IL6 and pulmonary fibrosis: A similar approach has been fruitful in SSc for serum IL6 and lung function decline, in idiopathic pulmonary fibrosis with serum MCP1 predicting respiratory outcome, and in SSc-associated pulmonary arterial hypertension (PAH), where MCP1 showed relevant changes after treatment [21].